Autolus Therapeutics plc reported net product revenue of $21.1 million and deferred revenue of $7.6 million for the third quarter ended September 30, 2025. The company recorded a net loss per ordinary share of $0.30 for the quarter, compared to $0.31 for the same period in 2024. Cash, cash equivalents, and marketable securities totaled $367.4 million at September 30, 2025, down from $588.0 million at December 31, 2024, primarily due to net cash used in operating activities and a delayed R&D tax credit receipt of approximately $20.1 million. During the period, Autolus achieved 60 authorized treatment centers for AUCATZYL, ahead of target, and continued clinical data generation to support market growth and expansion.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Autolus Therapeutics plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9574015-en) on November 12, 2025, and is solely responsible for the information contained therein.